SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 4 USD
0.00%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
43.71
43.96
Year Range
42.45
59.68
Daily Change
+0.46%
Monthly Change
-12.90%
6 month change
-19.03%
Year Change
-18.63%
Previous Close
43.7 4
Open
43.8 5
Low
43.7 1
High
43.9 6
Volume
57
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 20 May 2014

Full document

Business Context and Reporting Period

This Form 8-K filing by Supernus Pharmaceuticals, Inc. covers events occurring on May 20, 2014, and May 22, 2014. The report details the results of the Company's Annual Meeting of Stockholders held on May 22, 2014, and the receipt of a milestone payment under a license agreement with United Therapeutics.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed is a $2.0 million milestone payment received from United Therapeutics on May 20, 2014. The filing notes that as of March 31, 2014, there were 42,046,083 shares of common stock outstanding.

Material Changes and Corporate Actions

  • Milestone Payment: The Company received a $2.0 million payment under its license agreement with United Therapeutics.
  • Stockholder Vote Results:
    • Proposal 1 (Directors): Frederick M. Hudson was elected with 30,055,532 votes for; Charles W. Newhall, III was elected with 28,238,749 votes for.
    • Proposal 2 (Convertible Notes): Stockholders ratified the flexible settlement feature for the 7.5% Convertible Senior Secured Notes due 2019 (30,077,255 votes for).
    • Proposal 3 (Equity Plan): Stockholders ratified an amendment to increase shares available under the 2012 Equity Incentive Plan (29,851,773 votes for).
    • Proposal 4 (ESPP): Stockholders ratified an amendment to increase shares available under the 2012 Employee Stock Purchase Plan (30,031,994 votes for).
    • Proposal 5 (Auditor): Stockholders ratified the appointment of Ernst & Young LLP as the independent public accounting firm (37,256,393 votes for).

Guidance, Outlook, and Risks

The Company announced it will provide a business update and host investor meetings during the Jefferies Healthcare Conference on June 4, 2014. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard incorporation of press releases by reference.

Investor Verification Checklist

  • Verify the impact of the $2.0 million milestone payment on the Company's cash position and future revenue recognition.
  • Review the attached press releases (Exhibits 99.1 and 99.2) for details on the United Therapeutics agreement and the upcoming business update.
  • Confirm the terms of the ratified flexible settlement feature for the 7.5% Convertible Senior Secured Notes due 2019.
  • Monitor the Company's presentation at the Jefferies Healthcare Conference on June 4, 2014, for updated operational and financial guidance.

News